CRL Charles River Laboratories
Intrinsic value$0.00
Price (at call)$293.35
Margin of safety
-100.0%
vs market (rating basis)
-79.4%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 3.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | -1.9% |
| Years to target margin | 5 |
| Sales-to-capital | 0.76 |
| Beta | 1.38 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 10.2% |
| Terminal WACC | 8.7% |
Valuation bridge
| PV of explicit FCFF | -1.60B |
| PV of terminal value | -380.54M |
| Equity value | 0 |
| ÷ shares → per share | $0.00 |
News
bullish +0.60 · 8 articles
- Here's Why You Should Hold Charles River Stock in Your Portfolio Now
- Is This the Right Time to Add CRL Stock to Your Portfolio?
- Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
- Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
- 3 Inflated Stocks We Approach with Caution
- Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?
- Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?
- CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.12B | 3.0% | -1.9% | -62.99M | 158.29M | -221.28M | -200.86M |
| 2 | 4.24B | 3.1% | -1.9% | -64.91M | 166.06M | -230.97M | -190.31M |
| 3 | 4.38B | 3.1% | -1.9% | -66.93M | 174.24M | -241.18M | -180.38M |
| 4 | 4.52B | 3.2% | -1.9% | -69.05M | 182.87M | -251.93M | -171.03M |
| 5 | 4.66B | 3.2% | -1.9% | -71.28M | 191.97M | -263.25M | -162.22M |
| 6 | 4.81B | 3.3% | -1.9% | -73.61M | 201.58M | -275.19M | -153.93M |
| 7 | 4.97B | 3.3% | -1.9% | -76.07M | 211.71M | -287.78M | -146.12M |
| 8 | 5.14B | 3.4% | -1.9% | -78.65M | 222.42M | -301.06M | -138.75M |
| 9 | 5.32B | 3.4% | -1.9% | -81.36M | 233.72M | -315.08M | -131.81M |
| 10 | 5.51B | 3.5% | -1.9% | -84.20M | 245.67M | -329.87M | -125.27M |
⚠ intrinsic value floored at 0 — the drivers imply the equity claim is worth less than the debt ahead of it · Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.